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ABBREVIATIONS
ADME Absorption, distribution, metabolism, and excretion
ADR Adverse drug reaction





CNV Copy number variation
CoD Cause of death
DNA Deoxyribonucleic acid
CYP2C19 Cytochrome P450, family 2, subfamily C, polypeptide 19
CYP2D6 Cytochrome P450, family 2, subfamily D, polypeptide 6
E.g. Exempli gratia (for example)
EM Extensive metabolizer
gMP Genetically predicted metabolizer phenotype
5-HT 5-hydroxytryptamine (serotonin)
HTR2B 5-hydroxytryptamine receptor 2B
5HTTLPR Serotonin transporter gene-linked promotor region
ICD-10 International classification of disease, 10th revision
I.e. Id est (that is)
IM Intermediate metabolizer
MAOA Monoamine oxidase A
MoD Manner of death
OR Odds ratio
PCR Polymerase chain reaction
P-gp Permeability glycoprotein
PM Poor metabolizer
RT-PCR Real-time polymerase chain reaction
SERT Serotonin transporter
SNP Single nucleotide polymorphism
SSRI Selective serotonin reuptake inhibitor
STR Short tandem repeat
UM Ultrarapid metabolizer





The functionality of a drug depends on its dose. “The right dose, for the right
patient, at the right time” has been a long-standing principle in medicine. With
too low of a dose, the desired response is not attained: with too high of a dose
unwanted side effects, and even death, may occur.
In  most  drugs,  the  dose  is  not  individually  tailored.  A  standard  dose  is
effective for most users but may result  in an insufficient response or severe
side effects for a certain population of users. Only recently has personalized
drug  therapy  become more  feasible  due  to  an  understanding  of  the  genetic
factors behind the fate of a drug in human body. Most of this progress is due
to the emerging field of pharmacogenetics and pharmacogenomics.
Genetic variation may shape drug response in multiple ways and
pharmacogenetic analysis prior to drug initiation can help prevent unwanted
outcomes. Depression is a known risk factor for suicide. Antidepressants, used
to treat depression, are a good example of drugs in which the effective dose
and correct plasma level should be attained shortly after initiation of the drug.
The most widely used antidepressants worldwide are currently selective
serotonin  reuptake  inhibitors  (SSRIs);  citalopram  and  escitalopram  are  the
most-sold  SSRIs  in  Finland.  Although  they  are  acutely  rather  non-toxic,
serious adverse effects may occur in a dose-dependent manner in case of poor
metabolism capacity or due to drug-drug interactions. A noteworthy problem
of SSRIs is insufficient treatment response. It has been suggested that
ultrarapid metabolism is one factor behind this unfavorable phenomenon.
In  this  study,  citalopram-positive  completed  suicide  cases  were
investigated.  It  was  hypothesized  that  among  these  cases,  considered  an
extreme population of antidepressant users, pharmacogenetic factors
affecting the treatment success of SSRIs would be enriched.
Post-mortem material may pose a challenge for genetic analysis. For this
reason,  the  material  used  for  the  study  (blood  stored  on  FTA  cards)  was
characterized for concentration and degradation status. After this baseline
work,  FTA  samples  from  suicide  cases  were  genotyped  for
pharmacogenetically relevant gene polymorphisms. In particular, variants
that affect citalopram pharmacodynamics and pharmacokinetics and variants
that affect serotonin metabolism were concentrated. In the genotyping
analyses, fragment length analysis, Sanger sequencing, and TaqMan
chemistry-based methods were used. The role of drug interactions and adverse
drug effects in suicide deaths was also evaluated. Serotonergic and arrhythmic
adverse effects received special attention, as citalopram itself holds potential
for these types of adversities.
It  was  found that  DNA is  rather  well  preserved  over  time  in  a  FTA card
matrix. Thus, in addition to highly sensitive forensic analysis,
pharmacogenetic  analysis  was  also  possible  using  this  material.  However,
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time-dependent DNA degradation does occur and has an effect  when larger
DNA fragments are amplified.
As  a  main  result,  pharmacogenetic  analysis  revealed  enrichment  of  a
combined group of genetically predicted extreme CYP2C19 phenotypes
(ultrarapid and poor metabolizers) among citalopram-positive suicide cases
compared to Finnish population controls. This was an interesting finding, as
it may indicate a higher incidence of poor treatment efficacy or elevated
toxicity of the antidepressant among suicide victims. Also, a trend between
increased post-mortem citalopram concentration and genetically predicted
CYP2C19 phenotype was observed. This trend needs to be investigated further
in larger sample set. In the interaction analysis, several drug interactions and
adverse effects were observed. In approximately 8% of drug poisoning cases,
the detected adversity was evaluated to have a significant contribution to the
fatal outcome.
Based on the obtained results, pharmacogenetic testing prior to initiation
of  SSRIs  could  be  beneficial.  In  a  medico-legal  context,  pharmacogenetic
analysis could elucidate the manner of death (suicide vs. accidental death) in
drug poisoning cases, especially if the background information is obscure. It
also  appears  that  the  role  of  drug  interactions  is  currently  underestimated.
These findings suggest that the evaluation of post-mortem toxicological results
and determination of manner of death could be improved by developing tools
that detect interacting drug pairs and call attention to drug metabolism




Medico-legal  investigations  provide  a  unique  source  of  data  to  study
unexpected natural and unnatural deaths (e.g., suicides). The information
obtained from post-mortem investigations can reveal patterns and trends,
which can ultimately lead to preventive acts. The National Suicide Prevention
Project  in  Finland,  carried  out  from  1986  to  1996,  is  an  example  of  a
multidisciplinary collaboration combining medical, social, and public health
expertise  (Lönnqvist  et  al.  1993;  Lönnqvist  et  al.  1995).  After  this  project,
suicide deaths showed clear decreasing trend; in 1990 the suicide rate was 30.2
per 100 000 individuals (49.2 for males and 12.4 for females), whereas in 2016
the  rate  was  14.3  (22.7  for  males  and  6.2  for  females).  The  decrease  is
especially notable in males.
Mental disorders are a background factor in the majority of suicide deaths
(Henriksson  et  al.  1993;  Lönnqvist  et  al.  1995).  Female  victims  suffer  more
commonly from depressive disorders and males from substance-use related
problems and personality disorders (Arsenault-Lapierre et al. 2004). Indeed,
the  cause  of  death  (CoD)  register  data  (Official  Statistics  of  Finland  2010)
contrasted to the antidepressant consumption data (Finnish Medicines
Agency  (Fimea)  and  Social  Insurance  Institution  of  Finland  (Kela)  2016)
suggests a correlation between increased antidepressant usage and decrease
in suicide rates.
It is known that not all users benefit from antidepressive medication (Barak
et al.  2011;  Finnish Medicines Agency (Fimea) 2013;  Jukic et  al.  2018).  The
reasons behind this phenomenon are unknown. As antidepressant usage as
such seems to have a beneficial effect on the number of suicides (Haukka et al.
2009), it is essential to understand the factors behind treatment failures. By
identifying these factors,  which may be partly  genetic,  it  may be possible to
further decrease the number of suicides.
Previous studies have shown that inter-individual variation in drug
response can result from pharmacogenetic factors (i.e., genetic variation in
genes encoding drug-metabolizing enzymes, transporters, and
pharmacodynamic targets of drugs) (Ingelman-Sundberg et al. 2007; Peters et
al. 2004). If pharmacogenetic factors are involved in antidepressant treatment
failures and thus contribute to suicide deaths, these factors should be revealed
by investigating medico-legal autopsy material, such as citalopram-positive
suicide deaths. In addition to the preventive aspect, pharmacogenetic analysis
can  produce  useful  information  for  the  medico-legal  field  and  possibly
facilitate the interpretation of post-mortem toxicological results. With this
information one may be able to answer questions such as “How significant of
a  role  can  poor  metabolism  capacity  have  in  elevated  post-mortem  drug
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concentrations?” or “Could slightly elevated drug concentrations result from
genetically compromised drug metabolism rather than intentional overdose?”
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3 REVIEW OF THE LITERATURE
3.1 PHARMACOGENETICS
Pharmacogenetics can be defined as the study of the influence of inherited
factors  on  drug  response  (Vogel  F  1959).  Pharmacogenetic  studies  aim  to
understand how genetic differences between individuals modify the obtained
drug  response  and  the  drug  dose  required.  By  using  this  knowledge,
personalized treatments with proper dose, minimal side effects, and optimal
response can be attained.
The  roots  of  pharmacogenetics  are  in  the  1950s.  In  1952,  primaquine,  a
drug used to treat malaria, was observed to induce hemolytic anemia in some
patients  (Hockwald  et  al.  1952).  The  patients  were  found  to  suffer  from
glucose-6-phosphate dehydrogenase deficiency, leading to primaquine
sensitivity  and  the  observed  adverse  reaction  (Carson  et  al.  1956).  Almost
simultaneously,  inter-individual  variation  was  also  observed  among  other
drugs, such as isoniazid (Evans et al. 1960) and succinylcholine (Goedde et al.
1968; Kalow and Staron 1957). However, the molecular-level processes behind
adverse  drug  reactions  (ADRs)  were  not  revealed  until  the  1980s  when  a
genetic defect for a cytochrome P450 (CYP) 2D6 enzyme, affecting debrisoqine
metabolism, was characterized (Gonzalez et al. 1988).
Genetic variation may affect drug response in multiple ways. While defects
in drug pharmacokinetics are the most investigated aspects,
pharmacodynamic factors are also relevant (Ingelman-Sundberg et al. 2007).
Pharmacokinetics refers to individual’s ability to absorb, distribute,
metabolize, and excrete foreign compounds. These processes can be
abbreviated as ADME processes (Absorption, Distribution, Metabolism, and
Excretion). The purpose is to protect the body against harmful, exogenous
compounds. Thus, when a xenobiotic (e.g., a drug) is absorbed into the body it
is rapidly modified by various enzymes with phase I (phase I metabolism) and
phase  II  reactions  (phase  II  metabolism).  The  aim  of  these  reactions  is  to
modify the lipophilic compound to be more hydrophilic, and thus facilitate its
excretion. In phase I reactions, the compound is modified to be more reactive
by exposing or introducing polar groups. In phase II, highly polar groups (e.g.,
glucuronic acid) are introduced into the original compound or to the phase I
metabolite.
The processes mentioned above define the outcome of drug treatment as
well.  Depending  on  the  nature  of  the  compound (active  drug  vs.  pro-drug),
individual differences in metabolic capacity can lead to different outcomes
such as inadequate treatment response or ADRs. Inadequate treatment
response may result from ultrarapid metabolism (active drug) (Bertilsson et
al. 1985; Bertilsson et al. 1993) or from poor metabolism (pro-drug) (Sindrup
et  al.  1990).  ADRs  may  be  either  caused  by  poor  metabolism  capacity
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(accumulation  of  a  active  drug)  (Hamelin  et  al.  1996)  or  ultrarapid
metabolisim capacity (increased activation of pro-drug) (Kirchheiner et al.
2007). In addition to metabolic processes, inter-individual variation in drug
transporter genes can affect drug response, as multiple transporters
participate in absorption and excretion processes (Shitara et al. 2006).
Pharmacodynamics  refers  to  the  actual  effect  of  a  drug,  namely  its
interaction with the target molecule. A good example of a drug therapy where
both pharmacokinetic and pharmacodynamic factors are tested is
anticoagulant warfarin therapy. The treatment outcome of warfarin is a result
of its metabolism (catalyzed by CYP2C9 enzyme) and the expression level of
its pharmacodynamic target protein (vitamin K epoxide reductase (VKOR)).
Individuals with certain genetic variants of CYP2C9 and VKOR are considered
“warfarin sensitive” as they are in danger of over-anticoagulation, an adverse
effect of warfarin. Among warfarin-sensitive individuals, hemorrhagic
complications are possible with the standard dose used. Despite availability,
pharmacogenetic testing prior to initiation of warfarin medication is not
currently in routine use (Johnson et al. 2017).
3.1.1 PHARMACOGENETICS IN A MEDICO-LEGAL CONTEXT
Compared to clinical medicine, pharmacogenetics was introduced into a post-
mortem context far later (Druid et al. 1999; Levo et al. 2003; Pajarinen et al.
1996; Sallee et al. 2000; Savolainen et al. 1997). As genetic variation in genes
encoding drug-metabolizing enzymes can lead to severe ADRs and can even
cause fatal intoxications (Kupiec et al. 2006; Launiainen et al. 2010; Lazarou
et al. 1998; Madadi et al. 2010; Musshoff et al. 2010; Neukamm et al. 2013;
Sajantila et al. 2010), post-mortem pharmacogenetics can offer a useful tool
for the medico-legal field.
Compared to clinical pharmacogenetics, post-mortem aims are different.
First, as post-mortem research is accomplished in a selected population (i.e.,
deaths investigated by medico-legal autopsy), patterns and trends that
ultimately can lead to preventive acts can be revealed. Second, post-mortem
pharmacogenetics can provide defined information for interpretation of the
forensic toxicological results (Druid et al. 1999; Fonseca et al. 2016; Koski et
al. 2007; Koski et al. 2006; Levo et al. 2003). A more detailed interpretation
may  further  direct  the  manner  of  death  (MoD)  determination  (Koren  et  al.
2006; Koski et al. 2007). Without pharmacogenetic knowledge it can
sometimes be difficult to differentiate between accidental or intentional
poisoning deaths, especially when background information is scarce. Although
post-mortem pharmacogenetics could serve as a useful tool for post-mortem
toxicology and direct the MoD decision in certain deaths, it is not currently
part of routine investigations.
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3.2 MEDICO-LEGAL INVESTIGATIONS IN FINLAND
According  to  the  Finnish  law (1973/459,  7§),  a  medico-legal  cause  of  death
investigation  (CoD)  is  initiated  by  the  police  if  1)  death  is  not  known to  be
related to a disease or the deceased has not received medical treatment during
the last illness; 2) death is presumed to be related to an accident, homicide,
suicide, occupational disease, medical treatment, or war; or 3) it was otherwise
unexpected. At the end of the investigation, the cause and manner of death is
determined by a forensic pathologist. In 2016, approximately 16% of all deaths
in  Finland  underwent  a  medico-legal  autopsy  (Official  Statistics  of  Finland
2016a); the rate was even higher in the past (24% in 2009).
Based on the facts mentioned above, a suspected suicide always leads to a
medico-legal  investigation.  Statistics  relating  to  suicide  deaths  can  thus  be
considered exhaustive and reliable (Ylijoki-Sorensen et al. 2014). One of the
routine procedures in a medico-legal autopsy is to collect samples for forensic
toxicological analysis. During the years 2014 to 2016 forensic toxicological
analysis  was  performed  in  over  70%  of  medico-legal  autopsies  (personal
communication, Dr. Pirkko Kriikku).
Post-mortem toxicology is an invaluable tool when a possibility of fatal
drug poisoning is evaluated. The interpretation of the results, however,
demands special expertise as post-mortem drug concentrations are site-
(cardiac vs. femoral blood) and time-dependent (Pounder and Jones 1990;
Prouty and Anderson 1990). By collecting different samples (e.g., blood, urine,
vitreous humor, and hair), the time of drug consumption, acute ingestion vs.
continuous  use,  can  be  estimated.  Parent  drug-metabolite  ratios  can  also
reveal  if  the  drug  consumption  was  acute  or  chronic  (Druid  and  Holmgren
1997; Koski et al. 2007).
In suicides, the MoD is determined based on the underlying CoD and all
further information available (patient records, post-mortem toxicology report,
records of death circumstances, and evidence of intent e.g., farewell letter). If
the additional information is scarce it can be difficult to determine if the death
was intentional or unintentional (i.e., an accident). According to the World
Health Organization (WHO), a suicidal act should be defined as “self-infliction
of injury with varying degrees of lethal intent and awareness of motive” and
suicide as “suicidal act with fatal outcome” (World Health Organization 1968).
Thus,  cases  with  uncertainty  of  intention  should  be  classified  as
“undetermined”  deaths  (Lunetta  et  al.  2002).  The  majority  of  these
undetermined deaths result from fatal poisonings (Öhberg and Lönnqvist
1998).
A  good  example  of  a  medico-legal  case  were  the  MoD was  defined  to  be
undetermined  (i.e.,  the  possibility  of  suicide  could  not  be  excluded)  was
reported  by  Koski  et  al.  (Koski  et  al.  2007).  In  that  study,  post-mortem
toxicological findings were elegantly combined to pharmacogenetic data.
Koski et al. (2007) studied the tricyclic antidepressant doxepin, and observed
that poor metabolism capacity due to a genetic variation in CYP2D6 had most
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probably contributed to death. The MoD was concluded likely to be accident
and not suicide. It was observed that due to the genetic defect, the CYP2D6
enzyme-mediated pathway was not in use and thus the CYP2C19 enzyme-
mediated pathway (resulting in nordoxepin) showed elevated metabolite
concentrations. The increased parent drug-metabolite ratio revealed non-
acute use of drug and directed suspicions towards the metabolic defect of the
CYP2D6 enzyme. As mentioned previously, the parent drug-metabolite ratio
reveals if the drug consumption was acute or chronic but can also be used to
estimate the role of a genetic defect in drug metabolism.
3.2.1 TRENDS IN SUICIDE DEATHS IN 1921-2016 AND
ANTIDEPRESSANT CONSUMPTION IN 1990-2016
Statistics  Finland  maintains  the  Finnish  Cause  of  Death  (CoD)  register  and
collects yearly ICD-10 (World Health Organization 2011) coded data from the
death  certificates.  Suicide  mortality  has  been  followed  for  decades  and
summaries of suicide rates are provided annually (Figure 1).
The suicide rate in Finland has been rather high compared to other Nordic
countries (Titelman et al. 2013). The nationwide “National Suicide Prevention
Project  in  Finland”  was  carried  out  in  Finland  between  1986  and  1996
(Hakanen and Upanne 1996; Lönnqvist et al. 1993). The material was collected
within one year (1.4.1987-31.3.1988). All completed suicide cases (n = 1397,
males n = 1077 and females n = 320) within the time period were included
(Lönnqvist et al. 1993). Suicide cases were investigated with a psychological
autopsy  method  which,  in  addition  to  medico-legal  autopsy,  included
interviews of relatives and healthcare professionals.
After  the  highest  suicide  peak  (n  =  1512)  in  1990,  the  suicide  rate  (per
100,000 inhabitants) has been decreasing constantly (Figure 1). In 1990 the
rate was 30.2 (49.2 for males and 12.4 for females) and in 2016 (n = 787) the
rate was 14.3 (22.7 for males and 6.2 for females). The decrease is especially
prominent in males. In females there was a decrease but it is not as notable as
in males. The reason for this sex difference is currently unknown. In general,
the male:female ratio in completed suicides is approximately 3:1 in Finland.
Among  males,  the  use  of  violent  methods  is  more  common  compared  with
females, who tend to choose non-violent methods (i.e., self-poisoning)
(Denning et al. 2000; Pirkola et al. 2003).
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Figure 1 Suicide rates per 100,000 inhabitants in Finland from 1921-2016, stratified by sex
(Official Statistics of Finland 2010; Official Statistics of Finland 2011; Official
statistics of Finland 2012; Official Statistics of Finland 2013; Official Statistics of
Finland 2014; Official Statistics of Finland 2015; Official Statistics of Finland
2016b). The suicide rate was constantly increasing until 1990. Since then the rate
has decreased gradually. The National Suicide Prevention Project in Finland took
place during 1986-1996. It included three phases: research phase in 1987 (marked
with star and dotted line), implementation phase, and evaluation phase (Hakanen
and Upanne 1996).
The decreasing number of suicides coincided temporally with the National
Suicide Prevention Project in Finland, but the decrease in suicides obviously
depends on multiple factors such as the state of the economy, trends in alcohol
consumption (Hintikka et al. 1999), and societal changes (Fekete et al. 2001)).
However,  as  depressive  disorders  are  known to  be  a  risk  factor  for  suicides
(Henriksson et al. 1993) and better recognition of depression was one of the
aims of the project, it can be deduced that improved treatment of depression
(including  increased  use  of  antidepressants)  was  probably  one  of  the
underlying reasons (Figure 2) (Isacsson et al. 1997).
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Figure 2 Suicide rates from 1990-2016 (primary axis) (Official Statistics of Finland 2010;
Official Statistics of Finland 2011; Official statistics of Finland 2012; Official
Statistics of Finland 2013; Official Statistics of Finland 2014; Official Statistics of
Finland 2015; Official Statistics of Finland 2016b) vs. antidepressant consumption
(secondary axis) (Finnish Medicines Agency (Fimea) and Social Insurance
Institution of Finland (Kela) 2016; Finnish Medicines Agency (Fimea) and Social
Insurance Institution of Finland (Kela) 2017).
3.3 SELECTIVE SEROTONIN REUPTAKE INHIBITORS
Selective serotonin reuptake inhibitors (SSRIs) are currently the most
commonly used antidepressants in Finland (Figure 2). According to the
Finnish Medicines Agency (Fimea) sales report, the majority of SSRI sales is
due  to  two  compounds,  citalopram  and  escitalopram  (Finnish  Medicines
Agency  (Fimea)  and  Social  Insurance  Institution  of  Finland  (Kela)  2016;
Finnish Medicines Agency (Fimea) and Social Insurance Institution of Finland
(Kela) 2017). The difference between these two drugs is that citalopram is a
racemic mixture of pharmacodynamically active and inactive forms of S- and
R-enantiomers, respectively. Escitalopram contains only the active S-form
(Figure 3).
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Figure 3 Chemical structure of citalopram enantiomers. The figure was produced with
ChemDraw Professional 17.0 (PerkinElmer Informatics).
While the biological background of depression is still unknown, already in
the  1950s  key  observations  (Udenfriend  et  al.  1957)  leading  to  the
catecholamine hypothesis and the monoamine theory in the 1960s were
reported. These theories suggest that depression results from depletion of
serotonin, norepinephrine, and dopamine (Schildkraut 1965). It was proposed
that  depression  could  be  treated  by  increasing  amount  of  these  key
neurotransmitters. However, later studies have shown that this theory alone
was  far  too  simplistic,  and  a  more  complex  chain  of  events  (e.g.,
neuroplasticity  and  adult  neurogenesis)  seem  to  play  a  role  in  treatment
response (Castren and Hen 2013; Hyman and Nestler 1996).
SSRIs were invented in the early 1970s (Wong et al. 1974) as the role of low
serotonin was highlighted by multiple studies (Ashcroft and Sharman 1960;
Shaw et al. 1967; Åsberg et al. 1973). SSRIs increase the amount of serotonin
by inhibiting its  reuptake from the synaptic  cleft  to the presynaptic  neuron.
Prior to SSRIs, tricyclic antidepressants and monoamine oxidase A (MAOA)
inhibitors were used to treat depressive symptoms. Due to the less specific
mechanism of  action  (leading  to  side  effects)  and  narrow therapeutic  range
(Shaw et al. 1986) these drugs were rapidly replaced by SSRIs. Fluoxetine was
the first SSRI on the market (Wong et al. 1974), followed by citalopram a few
years later. Escitalopram was introduced most recently (in 2002) and arrived
to Finland in 2003 (Finnish Medicines Agency (Fimea) and Social Insurance
Institution  of  Finland  (Kela)  2016).  Since  then  its  usage  has  gradually
increased. In 2015 escitalopram usage surpassed that of citalopram. The usage
of other SSRIs, namely fluoxetine, sertraline, fluvoxamine, and paroxetine is
much lower (Finnish Medicines Agency (Fimea) and Social Insurance
Institution of Finland (Kela) 2016).
3.3.1 SSRIS MODIFY THE LEVEL OF KEY NEUROTRANSMITTER
SEROTONIN
Serotonin (5-hydroxytryptamine, 5-HT) was first discovered in 1948 from
bovine  serum  and  named  as  serotonin  due  to  its  localization  and
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vasoconstrictor properties (Rapport et al. 1948). A few years later it was also
identified from other locations, including the brain (Twarog and Page 1953).
In the central nervous system, serotonin serves as a chemical messenger
between nerve cells, or neurons. After neuronal excitation, serotonin is
released from the presynaptic neuron to the synaptic cleft. Serotonin diffuses
towards the postsynaptic receptors, which in turn deliver the message further.
The serotonergic action is terminated by serotonin transporters (SERT or 5-
hydroxytryptamine transporter, 5-HTT), the pharmacodynamic targets of
SSRIs. By inhibiting this transporter, SSRIs increase the amount of serotonin
in the synaptic cleft and thus prolong its effects. This has been associated with
alleviation of depressive symptoms.
Although  the  biochemical  change  in  serotonin  levels  is  rapid  after  the
initiation of  SSRIs,  the actual  treatment response is  obtained gradually and
takes usually weeks or even months to develop. However, remission and full
recovery is not achieved by all users. Some studies suggest that up to 50% of
SSRI users feel that they have not benefitted from their initial medication
(Barak et al. 2011; Finnish Medicines Agency (Fimea) 2013). The reason for
this is unknown.
Among genetic studies evaluating the inter-individual differences in SSRI
treatment response, one of the most intensively studied genetic
polymorphisms is the serotonin transporter gene-linked promotor region
(5HTTLPR) polymorphism.  This  regulatory  polymorphism  affects  the
promoter activity of the 5HTT gene  and  further  the  expression  level  of  the
transporter protein and ultimately decreases serotonin reuptake. The
5HTTLPR polymorphism is  characterized  by  two  length  variants,  known as
short (s) and long (l). The reduced gene expression is caused by the shorter
variant (Heils et al. 1996; Lesch et al. 1996). In addition, the transcriptional
efficacy of the 5HTT gene  might  be  affected  by  a  single  nucleotide
polymorphism (SNP), rs25531 A>G (Hu et al. 2006; Kraft et al. 2005; Philibert
et  al.  2008).  In  previous  studies,  the  ss  genotype  of 5HTTLPR has been
associated with poor antidepressant treatment response (Serretti et al. 2004;
Smeraldi  et  al.  1998;  Yu  et  al.  2002),  development  of  depression  after  a
stressful  life  event  (Caspi  et  al.  2003),  and  suicidality  (Bondy  et  al.  2000;
Courtet  et  al.  2001).  However,  converse  findings  have  also  been  published
(Kim et al. 2000).
In addition to 5HTT, other potential factors that can affect serotonin levels
or otherwise alter the obtained SSRI response are the monoamine oxidase A
(MAOA) enzyme and pre- and post-synaptic serotonin receptors (HTRs). The
mitochondrial  MAOA enzyme is  responsible for degradation of  serotonin in
the presynaptic neuron. Enhanced degradation of serotonin could possibly
lower the levels of releasable serotonin and indirectly affect SSRI treatment
response.  Then  again,  as  serotonin  receptors  are  responsible  for  both
termination of serotonin release and delivering the chemical message further,
alterations in these processes could potentially cause inter-individual
variation to drug response.
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In 2010, a specific HTR2B Q20* polymorphism was found (Bevilacqua et
al. 2010) with high frequency in the Finnish population but was absent or rare
in other populations. This polymorphism causes premature stop-codon
formation  in  the  serotonin  receptor  2B  coding  DNA  sequence  and  thus
disturbs  the  correct  formation  of  the  HTR2B  receptor  protein.  The HTR2B
Q20* polymorphism has been associated with impulsive violence (Bevilacqua
et al. 2010; Bevilacqua and Goldman 2013) and alcohol-related risk behavior
(Tikkanen et al. 2015). In MAOA there is also a polymorphism, monoamine
oxidase  A  upstream  variable  number  of  tandem  repeats  (MAOA-uVNTR)
which has been connected to extreme violent behavior (Tiihonen et al. 2015).
As impulsive and violent behavior may also precede a suicidal act, it has been
speculated that HTR2B Q20* and MAOA-uVNTR polymorphisms could be
involved as a background factors and increase the risk for completed suicide,
especially in combination with alcohol consumption (Bevilacqua et al. 2010).
3.4 PHARMACOKINETICS OF SSRIS WITH SPECIAL
FOCUS ON CITALOPRAM AND ESCITALOPRAM
CYP enzymes
SSRIs  are  metabolized  by  cytochrome  P450  (CYP)  enzymes.  In  the  case  of
citalopram and escitalopram, the most important metabolic enzyme is
CYP2C19. CYP enzymes are responsible for oxidative, phase I metabolism of
their substrates. Of the large CYP enzyme family, CYPs from families 1 to 3 are
mainly responsible for metabolism of  xenobiotics.  CYPs from other families
metabolize endogenous substances such as steroids and fatty acids. The most
important drug metabolism enzymes are CYP1A2, CYP2C9, CYP2C19,
CYP2D6, and CYP3A4 (Tornio and Backman 2018).
CYP enzymes are encoded by CYP genes. Human CYP genes are named as
follows: CYP written in italics represents “cytochrome P450” and refers to the
gene  (standard  capital  letters  referring  to  protein/enzyme),  followed  by  an
Arabic numeral showing a family and after a letter indicating a subfamily. The
last Arabic numeral identifies the individual gene within the subfamily (e.g.,
CYP2C19, CYP2D6) (Nebert et al. 1987; Nelson et al. 1993; Wain et al. 2002).
CYP genes are highly polymorphic. Due to the large number of variations,
a standard star (*)-allele nomenclature (Ingelman-Sundberg et al. 2000) and
a frequently updated database has been developed (Gaedigk et al. 2018). After
genotyping of the individual variants, the obtained result is translated into a
*-allele, which corresponds to haplotype. In this system, the *1-allele is
designated as the wild-type allele (defined by the absence of variants among
polymorphisms genotyped) and associated with normal enzyme activity.
Maternal and paternal *-alleles are then reported as combined diplotype
which represents the “CYP genotype” (e.g., CYP2C19 *1/*1).
Based on the defined genotype, the genetically predicted metabolizer
phenotype  (gMP)  can  be  determined  (Gaedigk  et  al.  2008).  In  the  case  of
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CYP2C19 and CYP2D6, four functional phenotype categories are commonly
used; poor metabolizers (PM, no enzyme activity), intermediate metabolizers
(IM, decreased enzyme activity), extensive or normal metabolizers (EM,
normal enzyme activity), and ultrarapid metabolizers (UM, ultrarapid enzyme
activity). It has been suggested that the genetically predicted metabolizer
phenotype would be indicated with “g” (e.g.,  gPM) (Gaedigk et  al.  2017),  as
also other factors, in addition to genetics, affect an individual’s metabolic
capacity.
As stated previously, citalopram and escitalopram are metabolized mainly
by  CYP2C19  but  the  CYP2D6  (and  to  a  lesser  extent  CYP3A4)  enzyme  also
participates (Figure 4). Both CYP2C19 and CYP2D6 are highly polymorphic.
Over 30 CYP2C19 and over 100 CYP2D6 allelic variants have been identified
and inter-individual variation in coding genes leads to notable differences in
drug metabolism capacity (Gaedigk et al. 2018).
Indeed, it has been shown that genetic variation in the CYP2C19 gene has
effects on citalopram and escitalopram concentration (Huezo-Diaz et al. 2012;
Jukic et al. 2018; Mrazek et al. 2011; Rudberg et al. 2008b). It is possible that
ultrarapid  metabolism  of  these  drugs  would  be  one  explanation  behind
insufficient treatment response and further therapeutic failure. Poor
metabolism capacity, leading to accumulation of the drug, can also potentially
predispose  individuals  to  severe  and  even  fatal  adverse  reactions,  such  as
arrhythmias (U.S. Food and Drug Administration (FDA) 2012; Vincenzi and
Lunetta 2015), in a dose-dependent manner.
In  a  recent  publication  by  Jukic  et  al.  (2018),  it  was  revealed  that
escitalopram treatment failure measured by switch from escitalopram to
venlafaxine  or  another  SSRI  was  most  common  among  escitalopram  users
defined either as UM or PM by CYP2C19 genotype. Based on the results, it was
concluded that genotype-guided dosing of escitalopram should be considered
as routine clinical practice, as the fraction of patients who switch to another
antidepressant  was  approximately  12%  in  reference  group  (with CYP2C19
*1/*1  genotype)  and  approximately  30%  in  extreme  phenotype  groups
(CYP2C19 *17/*17 and CYP2C19 loss-of-function/loss-of-function genotypes)
(Jukic et al. 2018).
In CYP2C19, the gUM phenotype results from CYP2C19*17, a regulatory
polymorphism located in the 5’ flanking region of the CYP2C19 gene (Sim et
al. 2006). The loss-of-function gPM phenotype most commonly results from
the *2-allele (de Morais et al. 1994b), although multiple other non-functional
alleles  (e.g.,  *3-allele  (De  Morais  et  al.  1994a)  and  *8-allele  (Ibeanu  et  al.
1999))  have  also  been  identified.  Based  on  the  measured  drug  plasma
concentrations, the effect of the loss-of-function variant seems to be more
notable compared to the effect of the increased-function variant (CYP2C19*17)
(Rudberg et al. 2008a). It is recommended that in the case of CYP2C19 gPM,
the citalopram/escitalopram dose should be decreased from the standard dose
(Hicks et al. 2015).
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Figure 4 Metabolism of citalopram. The first metabolism phase from citalopram to
demethylcitalopram is mainly catalyzed by the CYP2C19 enzyme. The CYP2D6
enzyme is responsible for the second demethylation step. In addition to
demethylation, other modifications (N-oxidation, oxidative deamination, and
glucuronide conjugation) are also possible (not shown) (Baselt 2000). Both S- and
R-enantiomers of citalopram are metabolized by the same CYP enzymes. For
simplicity, stereochemistry is not represented in this figure. The figure was
produced with ChemDraw Professional 17.0 (PerkinElmer Informatics).
In  addition  to  metabolic  functions,  the  CYP2D6  and  CYP2C19  enzymes
have also been suggested to participate in endogenous functions as both are
also expressed in brain tissue (Ahlner et al. 2010; Yu et al. 2003). Although
some studies have found an association between brain expression and mental
disorders, these associations are poorly understood (Jukic et al. 2017; Stingl
et al. 2013).
P-glycoprotein
In  addition  to  metabolic  enzymes,  transporter  proteins  also  participate  in
pharmacokinetic processes (absorption, distribution, and excretion). P-
glycoprotein (permeability glycoprotein, P-gp) functions as a gate-keeper
transporter in multiple body barriers (Cordon-Cardo et al. 1989; Thiebaut et
al. 1987). By pumping exogenous compounds out from inner compartments
(e.g., from brain tissue to the blood circulation and from intestinal epithelial
cell  back  to  the  gut  lumen)  it  protects  the  body  from  harmful,  exogenous
compounds. P-gp has a large substrate spectrum that varies from endogenous
steroids (Uhr et  al.  2002) to exogenous substrates such as drugs (Uhr et  al.
2003).
The pharmacological effect of a drug depends on its availability at the target
site. Thus, when considering antidepressants, their ability to cross the blood-
brain  barrier  (BBB)  is  one  of  the  main  considerations  of  drug  design.
Citalopram has been shown to be a substrate for P-gp (Uhr et al. 2008). Based
on  animal  studies,  the  brain  concentration  of  citalopram  is  affected  by  the
ABCB1 gene, which encodes P-gp. In abcb1-/abcb1- knock-out mice, the
citalopram concentration was higher compared to abcb1+/abcb1+ wild-type
mice (Karlsson et al. 2013). In humans, the three most commonly investigated
SNPs in the ABCB1 gene are 1236C>T, 2677G>T/A, and 3435C>T. Of these,
ABCB1 3435C>T was originally associated with decreased expression or
function of P-gp, or both (Hoffmeyer et al. 2000). However, as this SNP does
not cause an amino acid change, it was suggested that 3435C>T is in linkage
disequilibrium with  some other,  functional  SNP (Tanabe  et  al.  2001).  Soon
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thereafter, linkage disequilibrium between ABCB1 3435C>T, 2677G>T/A, and
1236C>T (Horinouchi et al. 2002; Kim et al. 2001) was confirmed. Despite the
original findings, the effect of the 3435C>T, 2677G>T/A, and 1236C>T ABCB1
polymorphism on P-gp expression remains controversial (Breitenstein et al.
2015; Owen et al. 2005).
As  decreased  function  of  the  P-gp  transporter  protein  may  cause  dose-
dependent adverse effects, ABCB1 gene polymorphisms have also received
medico-legal  attention  (Neuvonen  et  al.  2011).  Compared  to  CYP  enzymes,
altered  P-gp  function  seems  to  have  only  a  minor  effect  on  plasma  drug
concentrations. However, it is possible that these minor differences become
important in the brain.
3.5 ADVERSE DRUG INTERACTIONS IN CITALOPRAM-
POSITIVE SUICIDES
In  addition  to  genetic  factors,  drug  interactions  and  adverse  effects  also
explain poor treatment compliance. It was already suggested at the end of the
1990s by Druid et al. that forensic cases with suspicious toxicological findings
should be investigated for genetic defects and drug interactions (Druid et al.
1999).  According  to  the  WHO,  an  adverse  drug  reaction  is  defined  as  “a
response to a drug which is noxious and unintended, and which occurs at doses
normally used in man” (World Health Organization 1972).
Drug  interactions  can  be  classified  based  on  their  mechanism,  namely
pharmacodynamic and pharmacokinetic interactions (Palleria et al. 2013). In
pharmacokinetic interactions, the drug concentration is affected by some
other drug. These interactions may occur in all ADME phases. In the metabolic
phase, CYP–mediated interactions (induction or inhibition) are most common
(e.g., inhibition of CYP2C19 by fluconazole). In the absorption and excretion
phases, transporter-mediated interactions (e.g., inhibition of P-gp by
verapamil) may occur. Compared to concentration-related pharmacokinetic
interactions, pharmacodynamic interactions are usually additive (i.e., both
drugs have similar effects). This means that interacting drugs do not affect the
concentration of the other.
Citalopram is a very common finding in post-mortem toxicology
(Launiainen and Ojanperä 2014) and has the potential for both arrhythmic
and serotonergic adversities. When considering citalopram-positive suicide
cases, these adversities are of great interest (Deshmukh et al. 2012; Musshoff
et al. 1999) but are impossible to detect post-mortem (Vincenzi and Lunetta
2015).  An  example  of  a  drug  pair  with  a  pharmacodynamic,  arrhythmic
interaction is citalopram and levomepromazine. Both drugs prolong the QT-
interval  of  the heart  (Ozeki  et  al.  2010; U.S.  Food and Drug Administration
(FDA) 2012). When these drugs are used simultaneously, the risk of serious
arrhythmia leading to sudden cardiac death is increased. Serotonin syndrome
(Sternbach  1991)  may  develop  from  simultaneous  use  of  two  serotonergic
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antidepressants or concomitant use of e.g., citalopram and tramadol. Although
serotonin syndrome has characteristic symptoms and is thus rather easy to
recognize  in  medical  care  (Sternbach  1991),  most  of  the  medico-legally
investigated deaths occur without eyewitnesses.
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4 AIMS OF THE STUDY
The aim of this thesis was to investigate the role of pharmacogenetic factors in
suicides of citalopram-treated persons. We hypothesized that genetic factors
causing either insufficient response to treatment or adverse effects would be
enriched in this extreme population of antidepressant users. In addition, the
effect of a genetically predicted CYP2C19 metabolizer phenotype on measured
post-mortem citalopram concentrations and the role of adverse interactions
in suicidal poisoning deaths was evaluated. Before genotyping the actual study
population, the quality and quantity of FTA material used was characterized.
The detailed aims of the individual studies were:
I. To investigate the time-dependent DNA degradation and its effect
on  the  quality  and  quantity  of  DNA  obtained  from  dried  blood
samples,  preserved  on  FTA  card  matrix.  Based  on  this  study,  the
amount  of  the  FTA  sample  used  for  the  extractions  and  methods
used for the pharmacogenetic analysis were determined.
II. To investigate if 5HTTLPR, rs25531, MAOA-uVNTR, and HTR2B
Q20* polymorphisms, previously associated with poor treatment
response and aggressive behavior, are enriched among citalopram-
positive completed suicides compared to citalopram-positive post-
mortem  controls.  The  effect  of  alcohol  in  suicide  deaths  was  also
evaluated.
III. To assess if the ABCB1 1236T-2677T-3435T haplotype, associated
with lower transport function of P-glycoprotein, is enriched among
completed suicides of citalopram users.
IV. To investigate the role of clinically relevant CYP2C19 and CYP2D6




5 MATERIALS AND METHODS
5.1 SAMPLES
Data mining and toxicological samples
The  study  population  was  searched  from  the  post-mortem  forensic
toxicological database, which is maintained by the Laboratory of Forensic
Toxicology, University of Helsinki (currently the Forensic Toxicology Unit,
National Institute for Health and Welfare). The case inclusion was based on
the positive citalopram finding measured from post-mortem blood (Rasanen
et  al.  2003).  All  toxicological  analyses  were  performed  from  femoral  blood
samples containing 1% sodium fluoride. Samples were stored at +4 C after the
autopsy.
Only cases investigated at the Department of Forensic Medicine, University
of Helsinki were included in the study. Cases were further filtered by the
defined MoD, suicide vs. other than suicide (excluding undetermined deaths).
Control cases with MoD as accident were reviewed with caution. Controls were
pairwise  matched  with  cases  by  sex,  age  (±10  years),  and  blood  alcohol
concentration (BAC) (±1‰).
Dried post-mortem blood samples on FTA card
After study group formation, blood samples taken during autopsy and stored
as  dried  blood  spots  on  Whatman™  FTA  Gene  cards  (GE  Healthcare  Bio-
Sciences Corp., NJ, USA) were collected from the archive. Samples had been
collected  routinely  during  the  autopsies  in  addition  to  all  other  forensic
samples.  After  collection  and  initial  drying,  samples  were  stored  at  room
temperature inside an envelope with desiccant pack and protected from light
and humidity. As blood samples were missing for a few cases identified during
the  data  mining  (8/357),  the  study  population  eventually  included  349
citalopram-positive suicide cases and 284 citalopram-positive control
samples.  The  lower  number  of  controls  was  due  to  the  distortion  of  age
distribution, suicides comprising younger individuals.
Prescription and purchase data
Individual toxicological findings cannot reveal whether the positive post-
mortem finding is due to prescription-based usage or only random ingestion
of  drugs.  We  aimed  to  estimate  prescription-based  usage  by  purchase
information. All medical purchases in individual pharmacies are entered into
the register of national health insurance reimbursed prescription medicines.
The register is maintained by Kela, the Social Insurance Institution of Finland.
The registered variables include e.g., the unique personal identity number
issued to all residents in Finland, which permits the linkage with autopsy data
(data from death certificates and forensic toxicological database).
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The prescription and purchase data were requested based on the findings
from forensic toxicological analysis and the drug’s reimbursability. The dates
of  prescription  and  purchase  were  requested  for  the  following  drug
compounds specified with codes of the Anatomical Therapeutic Chemical
(ATC) classification system (WHO Collaborating Centre for Drug Statistics
Methodology 2018): N02 analgesic drugs (N02AA, N02AB, N02AC, N02AE,
N02AJ, N02AX), N03 antiepileptic drugs (N03AE, N03AF, N03AG, N03AX),
N05 psycholeptic drugs (N05AA, N05AB, N05AC, N05AD, N05AE, N05AF,
N05AG, N05AH, N05AL, N05AN, N05AX, N05BA, N05BB, N05BE, N05CD,
N05CF), N06 psychoanaleptic drugs (N06AA, N06AB, N06AG, N06AX,
N06BA,  N06CA),  N07  other  nervous  system  drugs  (N07BC),  C07  beta-
blocking agents (C07AA, C07AB), and M3 muscle relaxants (M03BC,
M03BX). Requested prescription and purchase information covered 12
months preceding death.
5.2 LABORATORY METHODS
Before processing the actual  samples (Studies II-IV),  smaller  set  of  samples
(Study I) was extracted and quantified to characterize the DNA quantity and
quality  on  the  FTA  cards.  Samples  for  study  I  were  selected  among  study
population samples. We aimed to select four random samples from eight time
points,  covering the investigated time period of  1998 to 2013 (n = 32).  This
enabled an estimation of time-dependent degradation of the samples and
more targeted selection of genotyping methods.
DNA extraction
Samples from study I were extracted identically to the actual samples. DNA
extraction from FTA cards was performed with a semi-automated
AutoMate Express™ Forensic DNA Extraction System using PrepFiler
Express™ Forensic DNA Extraction Kit (Applied Biosystems™, ThermoFisher
Scentific). The difference between actual and study I samples was the amount
of input material used and the number of parallel samples.
In study I, FTA cards were pierced with a Harris Micro-Punch™-puncher
(Ted  Pella,  Inc.,  Redding,  CA,  USA).  Four  2.0  punches  were  used  for  each
extraction. Each sample was extracted in triplicate. Based on the results, the
amount of input material was increased for actual samples and approximately
one fourth of the card’s marked area was used for the DNA extractions (Studies
II-IV). Actual samples were cut with scissors. In both DNA extraction sets, a




In  study  I,  DNA  samples  were  quantified  twice.  Triplicates  were  first
quantified to estimate internal sample variation and sample-to-sample
variation. A second quantification was performed after pooling of triplicate
samples.  Actual  samples were quantified only once.  In all  quantifications,  a
Quantifiler™  Human  Plus  (HP)  DNA  Quantification  Kit  (Applied
Biosystems™) was used. This kit evaluates the total amount of human DNA
and the quality, degradation, and inhibition level.
The  DNA  quality  evaluation  of  Quantifiler  HP  is  based  on  real-time
polymerase  chain  reaction  (RT-PCR).  During  the  RT-PCR,  two  DNA
fragments  (a  small  [80  bp]  and  a  large  [214  bp]  autosomal  target)  are
amplified simultaneously. After amplification, the DNA degradation level is
assessed by dividing the measured concentration of the small fragment with
the  concentration  of  the  large  fragment.  This  ratio  is  defined  as  the
degradation index (Applied Biosystems (Thermo Fisher Scientific) 2017). A
degradation index over one indicates poor amplification success of the large
fragment compared to the small fragment, and hence degradation of the
sample.
The kit also allows assessment of inhibition. This is based on amplification
success of the internal positive control (IPC) included in the assay. Inhibiting
agents present in a sample cause lower amplification success of the IPC. This
is  seen  as  a  shift  in  the  cycle  threshold  value  (Applied  Biosystems  (Thermo
Fisher Scientific) 2017).
All  samples  were  analyzed  with  a  7500  Real-Time  PCR  system.  Data
analysis was performed with the Human identification (HID) Real-Time PCR
Analysis Software v1.2 (Applied Biosystems™).
Genotyping
Study I
To elucidate the actual effect of time-dependent degradation on archived post-
mortem DNA samples, samples were analyzed with a highly sensitive forensic
assay and by amplifying the pharmacogenetically interesting CYP2D6 gene.
Samples were first amplified using a highly sensitive short tandem repeat
(STR)  kit  (GlobalFiler™ PCR amplification  kit,  Applied  Biosystems™).  This
kit is routinely used for forensic case work samples. In this assay, the amplicon
size varies between 75 to 444 bp. The samples were then amplified with a long-
PCR  reaction  targeting  the  large  (5.1  kb)  genomic CYP2D6 gene fragment
(Sistonen et al. 2005). For these amplification reactions, DNA samples were
normalized  for  2  and  35  ng,  respectively,  based  on  the  DNA  concentration
determined in a previous phase. The amplified DNA fragments were separated
using a capillary electrophoresis (3500xL Genetic Analyzer, Applied
Biosystems™) instrument (STRs) and the 2100 Bioanalyzer Instrument
(Agilent Technologies) (CYP2D6).  The  results  were  analyzed  with
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GeneMapper® ID-X ver. 1.4 software and Bioanalyzer with 2100 Expert
Software, respectively.
Studies II-IV
The  genotyping  methods  used  in  studies  II-IV  were  chosen  based  on  the
results  from study I.  In addition to study I,  genotyping forstudies II  and III
were performed in the Laboratory of Forensic Biology, Department of Forensic
Medicine, University of Helsinki. Genotyping for study IV was performed in
collaboration  with  Professor  Mikko  Niemi’s  research  group,  Department  of
Clinical Pharmacology, University of Helsinki.
5HTTLPR, MAOA-uVNTR, and rs25531 (Study II)
To  analyze  the  length  polymorphisms  (5HTTLPR and MAOA-uVNTR),
samples were normalized to 2 to 10 ng/μl  DNA concentration based on the
defined DNA quantity. Primer sequences used for the amplification were
previously published by Nakamura et al. (Nakamura et al. 2000) and Sabol et
al.  (Sabol  et  al.  1998).  For analysis  purposes,  the original  primer sequences
were modified to include fluorescent label. PCR-amplified fragments were
separated with a 3500xL Genetic Analyzer with GeneScan™ 1200 LIZ® Size
Standard for the fragment length determination. Interpretation of the results
was performed with GeneMapper® ID-X ver. 1.4 software.
Correct  allele  calls  for 5HTTLPR and MAOA-uVNTR were verified with
Sanger sequencing of representative alleles. Sequencher v.4.10.1 software
(Gene Codes) was used for data analysis.
After  verification,  the  PCR  products  of  the  samples  with  a  long  l  allele
(homo- or heterozygote) of the 5HTTLPR were  digested  with  the MspI-
restriction enzyme to identify the rs25531 polymorphism. Digested samples
were run along with a 500LIZ™ size standard with a capillary electrophoresis
instrument and analyzed with GeneMapper® ID-X  ver.  1.4.  For  details  of
5HTTLPR, MAOA-uVNTR, and rs25531 genotyping, see study II.
HTR2B Q20* and ABCB1 polymorphisms (Studies II and III)
Genotyping of the HTR2B Q20* and ABCB1 (1236C>T,  2677G>T/A,  and
3435C>T) polymorphisms was performed with TaqMan Genotyping Assays
(Applied Biosystems™). For genotyping, both custom TaqMan SNP
Genotyping Assays (HTR2B Q20*, ABCB1 1236C>T, 2677G>T, and 3435C>T)
and  TaqMan  Drug  Metabolism  Assay  (ABCB1  2677G  >  A,  assay  ID
C_11711720D_40) were used. Primer sequences for custom assays were
obtained  from  the  publications  by  Bevilacqua  et  al.  (for HTR2B Q20*)
(Bevilacqua et al. 2010) and Neuvonen et al. (for ABCB1 1236C>T, 2677G>T,
and 3435C>T) (Neuvonen et al. 2011). Genotyping was performed according




Genotyping of CYP2C19 and CYP2D6 polymorphisms (Study IV)
In study IV, samples were genotyped for the clinically relevant CYP2C19 and
CYP2D6 polymorphisms and for CYP2D6 copy  number  variation  (CNV).
Depending on the subsequent analysis, samples were normalized either to 5
ng/μl DNA concentration (TaqMan® Copy Number Assay and TaqMan®
OpenArray™ with preamplification reaction, Applied Biosystems™) or to 30
to 50 ng/μl DNA concentration (TaqMan® OpenArray™ without
preamplification reaction). Samples with DNA <30 ng/μl were preamplified
prior to OpenArray reactions. Genotyping was performed according to the
manufacturer’s  instructions  with  QuantStudio™  12K  Flex  Real-Time  PCR
System (Applied Biosystems™) and the obtained genotype data was
interpreted using the following software: TaqMan® Genotyper Software ver.
1.3 (OpenArray results) and CopyCaller® Software ver. 2.1 (CNV results).
CYP2D6 copy number variation was primarily determined with the assay
targeting exon 9 (Hs00010001_cn) of the CYP2D6 gene. If the amplification
success  was  poor,  two  additional  CNV  assays  that  targeted  introns  2
(Hs04083572_cn) and 6 (Hs04502391_cn) of the CYP2D6 gene were used.
An assay targeting the human RNase P H1 RNA gene was used as a reference
assay.
In study IV, Finnish population samples were used as genotyping controls.
The genotypes and demographic information for these samples was provided
by Professor Mikko Niemi.
5.3 INTERACTION ANALYSIS
In  study  IV,  all  forensic  toxicological  findings  detected  among  the  suicide
victims were searched for relevant adverse drug-drug interaction pairs or risk
cumulations. Drugs used for resuscitation purposes (flecainide, lidocaine, and
propofol)  were  excluded  from  the  analysis,  as  use  of  these  drugs  is  not
intentional  even  though  they  appear  in  forensic  toxicological  analysis.  The
search was performed using the online database Riskbase/Inxbase v.
Q4/2017-Q2/2018 (Medbase Ltd,  Turku,  Finland).  The database grades the
interaction pairs by clinical significance (A-D) and level of documentation (0-
4). Only clinically significant interactions and risk cumulations with all levels
of documentation (class D0-D4) were included in the study.
Identified interaction pairs were characterized as pharmacokinetic or
pharmacodynamic  and  further  divided  into  the  following  four  groups:
serotonin syndrome (SS), arrhythmias (A), sedation (SE), or other (O),
including mixed cardiovascular and central nervous system adversities.
Cases  were  first  analyzed  as  a  whole  and  then  at  subgroup  level  by
excluding cases with any single toxic drug concentration or blood/urine
alcohol concentration ≥3‰. Post-mortem femoral blood reference values
were used to evaluate the toxic drug concentration level in post-mortem
settings (drug concentration above post-mortem upper 95th percentile [mg/l])
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(Launiainen  and  Ojanperä  2014).  The  suicidal  intention  of  drug  intake  was
evaluated from death certificates (circumstances of the death). The
assessment of concurrent lifetime drug use vs. random ingestion of drugs was
based on purchase information obtained from Kela (Figure 5).
Figure 5 Drug interaction evaluation scheme.
5.4 STATISTICAL ANALYSIS
In  study  I,  the  effect  of  storage  time  on  DNA  yield  and  degradation  was
estimated by plotting the measured concentrations and DI values against the
storage time. Statistical significance was evaluated with Pearson Correlation
Coefficient using IBM SPSS Statistics software, version 22 (Armonk, NY).
For  all  genetic  SNP  and  VNTR  markers  in  studies  II  to  IV,  allele  and
genotype frequencies were estimated with Arlequin software version 3.5.1.2
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(Excoffier and Lischer 2010). Departure from Hardy-Weinberg equilibrium
(HWE) was tested using χ2-test. In the case of X-chromosomal MAOA, HWE
was tested only among females. Cases and controls were tested separately with
all markers. ABCB1 haplotypes were inferred from genotype data using
PHASE software version 2.1 (Stephens and Scheet 2005; Stephens et al. 2001).
Summary statistics for age, sex, and measured post-mortem citalopram and
alcohol concentrations were calculated with RStudio, versions 0.99.486, 1.0.
153, and 1.1.447 (RStudio Team 2016 2016).
In  studies  II  and  III,  binary  logistic  regression  analysis  implemented  in
Rstudio  was  used  to  estimate  the  association  between  genetic  markers  and
MoD. Statistical significance was evaluated with 95% confidence intervals
(CI). In study IV, Finnish population samples were used as controls, thus the
differences between cases and controls were tested with χ2-test implemented
in Rstudio. The statistical significance was evaluated by calculating binomial
proportion 95% CIs for the frequency point estimates.
5.5 PERMITS AND ETHICAL STATEMENT
The study was approved by the Coordinating Ethics Committee of the Helsinki
and Uusimaa Hospital District. The required permits for the scientific usage
of  autopsy  material  and  records  and  prescription  and  purchase  data  were
requested from the following responsible authorities: the National Institute
for Health and Welfare, the Regional (Southern Finland) State Administrative
Agency, and the Social Insurance Institution of Finland.
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6 RESULTS AND DISCUSSION
6.1 POST-MORTEM MATERIAL IN PHARMACOGENETIC
STUDIES (STUDY I)
It is known that post-mortem material may pose challenges for DNA analysis
(Bar  et  al.  1988).  The  quality  of  DNA  depends  on  post-mortem  interval
(Hansen et al. 2014), sampling site and tissue (Bar et al. 1988; Wheeler et al.
2017), and prevailing environmental conditions prior to sampling (Sorensen
et al. 2016).
Since the 1990s chemically treated filter papers that protect attached DNA
from nucleases and environmental factors have been available (GE Healthcare
Life Sciences 2011). DNA technology used in forensic settings is optimized to
overcome low amounts of DNA, the presence of inhibitors, and degradation
(Calacal et al. 2015). However, it was not known if dried post-mortem blood
samples preserved on FTA cards were suitable for other than highly sensitive
forensic applications targeting small amplicons, and how long such samples
can be stored for efficient DNA analysis in general.
In  study  I,  we  investigated  how  well  DNA  from  post-mortem  blood
collected during autopsy and stored on FTA cards is preserved over a 16-year
time period. This time period is equivalent to the preservation time of the post-
mortem samples investigated in studies II to IV. The main result of the study
was the following: DNA extracted from post-mortem blood dried on the FTA
card matrix is rather well preserved over time. Although time-dependent
degradation does exist, this mainly affects the methods that require large
amounts of long, intact DNA fragments.
Figure 6 Quantification (primary axis) and qualification (secondary axis) results from pooled
DNA samples. DNA concentration (grey bars) was shown to decrease and
degradation increase (black dots) over the preservation time.
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Extraction and quantification of sample triplicates revealed high variation
both within and between samples. Internal variation (i.e., differences in DNA
content between different spots on the same FTA sample) could be threefold
(e.g., from 12 ng/μl to 44 ng/μl [SD 16.1]). The reason for this is unclear but
may be due to post-mortem changes, such as formation of cell aggregates (Bar
et al. 1988) occurring before the sample is applied to the card. It is possible
that  altered  viscosity  of  the  blood  and  cell  aggregation  leads  to  unequal
distribution of the blood on the FTA card matrix. Across different samples, the
mean DNA concentration varied from 2 ng/μl (as minimum) to 27 ng/μl (as
maximum). None of the DNA samples showed traces of inhibition.
In  pooled  samples,  despite  few  individual  samples  with  high  DNA
concentrations,  the overall  trend showed that  the older the sample was,  the
less (amplifiable) DNA was obtained. The same was true when samples were
evaluated for degradation (Figure 6). In older samples, STR analysis showed a
clear downward trend in peak heights of longer amplicons. This trend was not
observed in more recent samples, where different-sized fragments amplified
equally well  (Figure 7).  Analysis  of CYP2D6 amplification results confirmed
the effect of degradation when analyzing longer DNA fragments.
Figure 7 Comparison of STR profiles of two samples, one originating from 1998 (a) and the
other from 2013 (b). In the GlobalFiler™ PCR amplification kit, 6-dye fluorescent
chemistry is used to differentiate the same-sized DNA fragments from each other.
Different colors used here correspond to the 6-dye system; blue (6-FAM™), green
(VIC™), yellow (NED™), red (TAZ™), and purple (SID™). The 6th dye (LIZ ™) is
used for size standard (not shown here). Peak heights are presented in relative
fluorescent units (rfu). The shortest locus included in each dye is shown on the left
end and the longest on the right end. In the 1998 sample (a), the time-dependent
degradation is evident. The longer the fragment is, the poorer is the amplification
success (lower fluorescence intensity). In the 2013 sample (b), all fragment lengths
seem to amplify equally well.
Based  on  the  results,  we  concluded  that  proper  quantification  of  post-
mortem samples with RT-PCR based methods is essential, as the variation in
DNA concentration and quality is high and the amount of sample is limited.
Due to the internal variation, we also concluded that for research purposes it
is more practical to cut a large piece from the FTA card with scissors rather




As  both  the  STR  and  the CYP2D6 analyses showed clear evidence of
degradation, we decided to utilize TaqMan chemistry-based methods and
highly sensitive capillary electrophoresis and RT-PCR instruments for
consequent genotyping. To maximize amplification success, rather short
(<400bp) amplicons were preferred in subsequent analyses if possible.
6.2 DEMOGRAPHICS OF CITALOPRAM-POSITIVE
SUICIDE VICTIMS DIFFER FROM UNSELECTED
SUICIDE POPULATION (STUDY II)
The number of suicide deaths in Finland have decreased significantly since
1990.  The  reasons  for  this  are  undoubtedly  multifactorial.  During  the  last
three years the number has been rather constant at less than 800 cases per
year (Official Statistics of Finland 2014; Official Statistics of Finland 2015;
Official Statistics of Finland 2016b). Despite the overall decrease of medico-
legal autopsies (Official Statistics of Finland 2016a), the Finnish legislation
and the medico-legal CoD investigation practice assures that the decrease has
had no effect on autopsy rates of suicide deaths. Thus, suicide statistics can be
considered  consistent  and  reliable.  Compared  to  many  other  countries,  the
number  of  medico-legal  autopsies  in  Finland  is  still  rather  high.  In  some
countries,  suicide  statistics  are  skewed  due  to  low  medico-legal  autopsy
frequency (Ylijoki-Sorensen et al. 2014).
Among Finnish suicide victims, males are over-represented compared with
females (3:1, respectively). Furthermore, males commit suicide more
commonly using violent methods. However, these general observations made
in  previous  studies  (Hakko  et  al.  1998;  Henriksson  et  al.  1993;  Lahti  et  al.
2014) were not true among the citalopram-positive suicide cases studied here.
In citalopram-positive suicide victims, the observed male-female ratio was
almost equal; 53% of suicides were committed by males and 47% by females
(Figure  8).  In  addition,  non-violent  suicides  were  exceptionally  common
among males (52%). The reasons behind these observations are possibly due
to the inclusion criteria used.
Results and discussion
36
Figure 8 Inclusion criteria for the study group selection.
The cases were selected based on the positive post-mortem citalopram
finding.  Most  of  the  cases  (85%)  had  a  valid  citalopram/escitalopram
prescription as well  (Study III).  Based on this,  we deduced that  citalopram-
positive suicide victims are practically the same as citalopram-treated suicide
victims.
The  enrichment  of  females  in  our  case  population  is  probably  because
depressive disorders (often treated with citalopram) are more common among
female suicide victims compared with males (Arsenault-Lapierre et al. 2004).
It has also been questioned if the higher incidence of depressive disorders is
biologically true or if females are only more willing to seek help (Kessler et al.
1981). Nevertheless, both explanations would lead to overrepresentation of
females in the study material.
One factor affecting the suicide method used is the availability (Öhberg et
al.  1995).  Thus,  as  most  of  the  individuals  received  medical  treatment  it  is
probable  that  they  had  easy  access  to  drugs.  This  could  explain  the  high
number of drug poisonings (Öhberg et al. 1998).
6.3 ENRICHMENT OF THE EXTREME CYP2C19
GENOTYPES – INDICATION OF A
PHARMACOGENETIC EFFECT? (STUDY IV)
One of the main goals of the National Suicide Prevention Project in Finland
was to investigate the role of mental health problems in suicide deaths with a
special focus on depression recognition and adequate depression treatment.
Suicides of young males also received special attention (Isometsä et al. 1994;
Lönnqvist  et  al.  1993).  There has been a notable decrease in the number of
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suicides  during  and  after  the  project.  However,  the  rate  is  still  rather  high
(Official Statistics of Finland 2016b). This raises the following question: were
some risk factors unreachable with the approaches used during the project?
Based on the general  suicide statistics,  one cannot conclude if  the observed
decrease has been due to decrease of violent, non-violent or both suicide types.
Pharmacogenetics entered the post-mortem field in the 1990s. It is
expected that if pharmacogenetic factors affect antidepressant treatment
success, this would be seen in our citalopram-treated suicide victims. Thus, by
assuming that suicide completers, who despite antidepressant treatment
commit suicide, are the same as those who will not benefit from antidepressant
medication,  it  is  possible that  suicide mortality  could be lowered further by
taking account pharmacogenetic differences.
In study IV, by concentrating on citalopram pharmacokinetics we observed
that the combined group of extreme gMPs (poor and ultrarapid metabolizers)
of citalopram/escitalopram metabolizing CYP2C19 were enriched among
completed suicide cases compared to the Finnish general population. This
observation is consistent with a recently published study (Jukic et al. 2018). In
that study, escitalopram users with poor or ultrarapid metabolism capacity
were observed to switch their antidepressant medication more often than
users with extensive metabolism capacity. It was also observed that in gUMs
the measured escitalopram concentration was under the therapeutic range.
Ultrarapid metabolism capacity was concluded to be a probable reason for the
switch. This gUM effect on citalopram concentrations could not be observed
in our post-mortem study. However, it has been shown that the effect of the
loss-of-function variant, causing poor metabolism capacity, is more notable
compared to the effect of the increased-function variant (Rudberg et al.
2008a). Also, the dosing recommendations of citalopram/escitalopram
consider  only  the CYP2C19 gPM  phenotype  (Hicks  et  al.  2015).  Thus,  it  is
possible that  even though the concentration of  citalopram would be slightly
lower  in  suicide  cases  determined  as  gUM,  small  genetic  effects  in  drug
concentration are covered by post-mortem redistribution after the death. In
the case of citalopram, the ratio between post-mortem blood and ante-mortem
plasma concentration is 3.6 (Launiainen and Ojanperä 2014), meaning that
citalopram has rather high redistribution characteristics after death.
Instead, we made an interesting medico-legal observation. The effect of the
genetically predicted CYP2C19 phenotype on measured post-mortem
citalopram concentration was evaluated among violent suicide victims
grouped by CYP2C19 phenotype (gPM, gIM, gEM or gUM).  It  was observed
that in the gPM group, the measured citalopram concentration was equal to
the 90th percentile citalopram concentration level defined by Launiainen and
Ojanperä  (Launiainen  and  Ojanperä  2014)  (Figure  9).  The  purpose  of  the
compilation  by  Launiainen  and  Ojanperä  was  to  provide  guidelines  for  the
interpretation of forensic toxicological results, as interpretation of post-
mortem drug concentrations often poses a challenge for forensic pathologist.
Upper percentile concentrations were defined as a possible indication of drug
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overdose. Based on the results shown here, it seems that CYP metabolizer
status may affect the interpretation of forensic toxicological results. However,
the observed trend needs to be investigated further in a larger sample set and
with other drug compounds.
Figure 9 Post-mortem mean (●) and median ( ) citalopram concentrations grouped by
CYP2C19 phenotype (genotype-predicted) and post-mortem mean, median and
upper percentile ( ) citalopram concentrations defined by Launiainen and Ojanperä
(2014). As highlighted with red boxes, the citalopram concentration in the gPM
group is equal to the 90th percentile citalopram concentration level (Launiainen and
Ojanperä 2014). The figure has been modified from (Rahikainen et al. 2018).
Based  on  these  results,  it  seems  that  the  citalopram/escitalopram
treatment response is affected by the CYP2C19 genotype. As similar result was
already obtained from another study (Jukic et al. 2018) as well, it appears that
pharmacogenetic analysis of depressed patients, especially those with suicidal
thoughts,  could  be  recommendable  prior  to  initiation  of  a  drug  treatment.
However, it seems that citalopram treatment response is only affected by
pharmacokinetic factors, as no association with the 5HTTLPR genotype
(pharmacodynamics) was found in study II. However, the expression level of
this  transporter  may  have  an  effect  on  the  stress  tolerance  of  a  depressed
individual (see below 6.4.2).
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6.4 DIFFERENCE IN SUICIDE RATIO BETWEEN MALES
AND FEMALES (STUDIES II-IV)
Sex differences in suicide statistics are an interesting phenomenon (Freeman
et al. 2017). Based on the national suicide statistics (Figure 1), it seems that
although  the  number  of  female  suicide  victims  has  consistently  been  lower
compared to males, females have also been less affected for the preventive acts
established. In all studies (II-IV), suicide cases were first analyzed as a whole
and after stratified by sex and suicide method used.
6.4.1 NON-VIOLENT SUICIDE; INTENTIONAL OR ACCIDENTAL DRUG
POISONING? ARE FEMALES WITH CERTAIN ABCB1 AND
CYP2D6 GENOTYPES MORE VULNERABLE TO ADVERSE DRUG
EFFECTS? (STUDIES III-IV)
In studies III and IV, enrichment of the ABCB1 1236T-2677T-3435T haplotype
and CYP2D6 gPM phenotype was observed among female suicide victims and
further among the non-violent subgroup of females. Both of these defective
genotypes cause accumulation of substrate drugs (Johne et al. 2002; Koski et
al. 2007). Enrichment of poor functioning genotypes in intoxication deaths
could suggest that females carrying these haplotypes or phenotypes are more
vulnerable to concentration-related drug adversities. It is possible that female
suicide  attempters  with  a  susceptible  genetic  background  are  in  danger  of
suicide death that is actually unintended. Indeed, attempted suicides seem to
be  more  common  among  females  (Freeman  et  al.  2017;  O'Loughlin  and
Sherwood  2005).  This  could  explain  the  lower  decrease  in  suicide  rates
compared to males and “resistance” for the preventive acts.
However, our case-by-case evaluation revealed only one CYP2D6 gPM case
with elevated concentration of a CYP2D6-dependent drug (amitriptyline) and
unclear  suicide  intention.  Thus,  no  clear  explanation  for  the  observed
enrichment  was  attained.  It  also  remains  unclear  why  the  same  genotypic
effect  was  not  observed  among  males  who  committed  suicide  by  drug
poisoning.
Both ABCB1 and CYP2D6 have also been associated with suicidal deaths in
other studies (Boiso Moreno et al. 2013; Zackrisson et al. 2010). However, the
biological mechanism behind the observed associations remains unclear.
Zackrisson et  al.  (2010) found enrichment of CYP2D6 gUMs among suicide
victims (intoxications excluded) compared with those whose MoD was defined
as  natural.  It  was  concluded  that  this  enrichment  might  be  linked  with
insufficient response to antidepressant treatment. However, no information
on the medical histories of these individuals was available (Zackrisson et al.
2010). In the Finnish population, the frequency of CYP2D6 gUM is rather high
(7.2%) (Pietarinen et al. 2016). In study IV, the frequency in citalopram-
treated suicide victims (7.7%) was observed to be close to the general
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population frequency. Thus, based on our results it seems that CYP2D6 is not
related  to  suicidality  in  general  or  personality  traits  at  least  in  citalopram-
related suicides (Ahlner et  al.  2010; Yu et  al.  2003).  However,  it  is  possible
that the ultrarapid phenotype of CYP2D6 could explain the insufficient
response  to  treatment.  For  this,  suicide  victims  treated  with  primarily
CYP2D6-dependent antidepressant should be investigated.
6.4.2 ASSOCIATION BETWEEN 5HTTLPR GENOTYPE AND SUICIDE
INTENTION, OBSERVATION FROM SUICIDE METHOD USED
(STUDY II)
The  results  from  study  II  highlighted  that  the  citalopram-positive  suicide
population is different than the unselected suicide population. However, it
also seems that the population investigated is internally heterogeneous. This
may  be  explained  by  the  fact  that  although  citalopram  is  a  first-line
antidepressant to treat depression, it is also used for other purposes such as
treatment of anxiety. As briefly mentioned in section 6.3, no association
between serotonin transporter variation and risk of suicide was detected when
the suicide population was analyzed as a whole. Thus, it can be concluded that
citalopram treatment success does not depend on the 5HTTLPR genotype.
However, stratification by sex and suicide method used revealed that the low-
functioning 5HTTLPR ss  genotype  possess  a  risk  for  violent  suicide  among
males.  This  was  an  interesting  finding  as  it  is  possible  that  the 5HTTLPR
genotype modifies the response to stress, which in turn works as a trigger for
suicidal act (Caspi et al. 2003), or relates to the depth of depression and high
suicidal intent, which is indirectly seen as a violent suicidal act.
No association between the risk of suicide and two other polymorphisms
investigated  in  study  II  (MAOA-uVNTR and HTR2B Q20*) was detected.
However, the BAC was only found to be a risk factor for non-violent but not
violent suicide. This is quite surprising. The association between non-violent
suicides  and  alcohol  is  clear  as  alcohol  potentiates  the  sedative  effects  of
multiple  drugs  (e.g.,  opioids  and  benzodiazepines).  However,  the  missing
association between alcohol and violent deaths is more difficult to explain.
Alcohol  is  frequently  associated  with  violent  suicides  (Lunetta  et  al.  2001;
Ohberg et al. 1996) as it increases self-confidence and may lower the threshold
of  suicide.  Furthermore,  suicide  cases  with  underlying  alcohol  use  disorder
(AUD) are more impulsive and aggressive compared to suicides without AUD
background (Chachamovich et al. 2012). But this was apparently not the case
in our material.  It  is  possible that  genetic  factors associated with aggressive
and impulsive behavior when under the influence of alcohol (Tiihonen et al.
2015;  Tikkanen  et  al.  2015)  do  not  have  a  role  in  violent  acts  committed
without alcohol.  Impulsive violence against  others might also be a different
phenomenon than violence against oneself (Jokinen et al. 2017). However, this
is  only  speculation,  as  we  did  not  have  ante-mortem  patient  records  and
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clinical diagnoses of suicide victims and thus knowledge of underlying AUD.
Overall, the missing background information is a clear limitation of all studies
included in this thesis.
6.5 ADVERSE DRUG INTERACTIONS IN FATAL DRUG
POISONINGS (STUDY IV)
Polypharmacy  is  common  phenomenon  in  forensic  toxicology,  especially  in
suicidal  intoxications  (Ohberg  et  al.  1996).  Thus,  uncovering  adverse  drug
interactions and ADRs is not surprising as such.
In study IV, six pharmacokinetic and 208 pharmacodynamic interactions
or risk cumulations were detected when the suicide population was analyzed
as a whole. The low number of pharmacokinetic interactions was consistent
with  a  previously  published  study  (Launiainen  et  al.  2009).  The  number  of
pharmacodynamic interactions seems at first very high. Considering that
pharmacodynamic interactions/risk cumulations are additive and a single,
high (toxic) drug concentration can overrun the effect of an interaction, the
relevance of an interaction as a contributory factor to poisoning death must be
interpreted cautiously. However, the role of pharmacodynamic interactions
should  be  kept  in  mind  as  in  8% of  all  drug  poisoning  deaths,  a  drug-drug
interaction most probably contributed to the fatal outcome.
Drug  adversities  may  lead  to  fatal  outcome if  a  person  is  susceptible  for
certain type of adversity due to genetic background (e.g., congenital long QT
syndrome (Lunetta et  al.  2002)) or liver impairment (Vincenzi  and Lunetta
2015). Pharmacodynamic interactions can be especially difficult to recognize
as  drug  concentrations  are  not  usually  particulary  high.  As  discussed  in  a
previous publication (Launiainen et al. 2009), the role of interaction is rarely
recognized  by  a  forensic  pathologist,  even  though  the  drugs  involved  were
recognized to have contributed to death. This observation was also confirmed
in study IV.
It is important to develop tools for better identification of potentially fatal
drug combinations. With database-aided, semi-automated identification, a
forensic  pathologist  could  more  readily  interpret  potential  interactions  in  a
particular case. In addition to interactions, toxicological drug findings in
which a drug’s metabolism is also affected by pharmacogenetic variation could
be automatically highlighted in the future to alert the forensic pathologist of a




In  Finland,  forensic  toxicological  analysis  is  performed  in  most  (>70%)
medico-legal autopsies. Traditional forensic genetic analysis concentrates on
crime scene samples, identification of human remains, kinship analysis, and
paternity testing. Despite promising findings, post-mortem pharmacogenetics
— an integrative discipline between forensic genetics and toxicology — is not
routine practice among medico-legal CoD investigations.
Although most medico-legal cases are solved without pharmacogenetic
testing, it is important to recognize in which types of cases genotype analysis
would  likely  give  relevant  information  for  the  CoD  investigation.  Increased
drug concentration may be due to multiple causes, such as intentional intake,
tolerance, pharmacokinetic interaction, or pharmacogenetic defect. Although
pharmacogenetic variation explains a rather small part of increased drug
concentrations,  as  shown in  this  thesis,  it  can  be  an  important  factor  in  an
individual case. As it is not cost-effective to genotype all cases, comprehensive
research  is  needed  to  be  able  to  trace  potential  cases,  in  which
pharmacogenetics  testing  may  open  a  new interpretation  of  the  CoD or  the
MoD.
In  this  study,  a  combined  group  of  extreme CYP2C19 phenotypes was
observed more frequently from citalopram-positive suicides compared with
population controls. It is thus possible that altered citalopram metabolism due
to pharmacogenetic factors has an adverse effect on treatment outcome. In
addition, a trend between the genetically predicted CYP2C19 phenotype and
post-mortem citalopram concentration was discovered, although no definite
conclusion could be drawn due to the rarity of the CYP2C19 poor metabolizer
phenotype.  This  finding  needs  to  be  investigated  further,  as  without
knowledge of the underlying genotype an increased drug concentration can be
falsely interpreted as intentional drug intake. This study also showed that in
addition to post-mortem pharmacogenetics, studies on drug interactions
deserve more attention in the realm of medico-legal autopsies. Lastly, we have
shown that post-mortem genetic studies are achievable from samples stored
for  more  than  a  decade.  In  conclusion,  post-mortem pharmacogenetics  has
shown  potential  both  in  clinical  practice  and  forensic  medicine,  and  more
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